Cognitive change in Parkinson disease

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 4, 2006, Pages 302-310

  Galvin, James E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dementia; Lewy body; Parkinson disease

Indexed keywords

ALZHEIMER DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROPSYCHIATRY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; REVIEW; SYNDROME DELINEATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 33845411869     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000213858.27731.f8     Document Type: Review

References (117)

1. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol. 2001;58:186-190.
2. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-148.
3. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol. 1998;44:S1-S9.
4. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology. 1990;40:1513-1517.
7. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal-study of dementia in Parkinson's-disease. J Neurol Neurosurg Psych. 1992;55:566-571.
8. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease - A community-based, prospective study. Neurology. 2001;56:730-736.
9. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20:1255-1263.
10. Javin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4 longtudinal study. J Geriatr Psychiatry Neurol. 2005;18:149-154.
11. Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol. 2005;58:773-776.
12. Breteler MMB, de Groot RRM, van Romunde LKJ, et al. Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma: a register-based follow-up study. Am J Epidemiol. 1995;142:1300-1305.
13. Rajput AH, Offord KP, Beard CM, et al. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology. 1987;37:226-232.
14. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;69:308-312.
15. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938-942.
16. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson disease. Arch Neurol. 1997;54:260-264.
17. Rippon GA, Marder KS. Dementia in Parkinson's disease. Adv Neurol. 2005;96:95-113.
18. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology. 2000;55:539-544.
19. Duncombe ME, Bradshaw JL, Iansek R, et al. Parkinsonian patients without dementia or depression do not suffer from bradyphrenia as indexed by performance in mental rotation tasks with and without advance information. Neuropsychologia. 1994;32:1383-1396.
20. Scogin F, Storandt M, Lott L. Memory-skills training, memory complaints, and depression in older adults. J Gerontol. 1985;40:562-568.
21. Stern Y, Marder K, Tang MX, et al. Antecedent clinical-features associated with dementia in Parkinsons-disease. Neurology. 1993;43:1690-1692.
22. Glatt SL, Hubble JP, Lyons K, et al. Risk factors for dementia in Parkinson's disease: effect of education. Neuroepidemiology. 1996;15:20-25.
23. Starkstein SE, Berthier ML, Bolduc PL, et al. Depression in patients with early versus late onset of Parkinson's disease. Neurology. 1989;39:1441-1445.
24. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal-study of depression, cognitive decline, and physical impairments in patients with Parkinsons-disease. J Neurol Neurosurg Psychiatry. 1992;55:377-382.
25. Troster AI, Moe KE, Vitiello MV, et al. Predicting long-term outcome in individuals at risk for Alzheimer's disease with the Dementia Rating Scale. J Neuropsychiatry Clin Neurosci. 1994;6:54-57.
26. Huber SJ, Freidenberg DL, Paulson GW, et al. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53:275-278.
27. Kuzis G, Sabe L, Tiberti C, et al. Cognitive functions in major depression and Parkinson disease. Arch Neurol. 1997;54:982-986.
28. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863-1872.
29. Parkinson J. An essay on the shaking palsy. In: Critchley M, ed. Reprinted in James Parkinson: A Bicentennial Volume of Papers Dealing With Parkinson's Disease. London, UK: McMillan Press; 1955:1777-1824.
30. Gibb WRG, Poewe WH. The centenary of Friederich H. Lewy. Neuropath App Neurobiol. 1986;12:217-221.
31. Gibb WRG. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropath App Neurobiol. 1986;12:223-234.
32. Pollack M, Hornabrook RW. The prevalence, natural history and dementia of Parkinson's disease. Brain. 1966;89:429-448.
33. Lewy FH. Die lehre vom tonus und der beweung. Springer Publishing, Berlin 1923. (German) cited in Gibb WRG, Poewe WH. The centenary of Friederich H. Lewy. Neuropath App Neurobiol. 1986;12:217-221.
34. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadraparesis in flexion. J Neuropathol Exp Neurol. 1961;20:237-244.
35. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006. In Press.
36. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2003;61:40-45.
37. Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr Neurol Neurosci Rep. 2006;6:169-176.
38. Thorpy MJ, Adler CH. Parkinson's disease and sleep. Neurol Clin. 2005;23:1187-1208.
39. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5:572-575.
40. Johnson DK, Morris JC, Galvin JE. Visuospatial and psychomotor deficits in Lewy body dementia: improving antemortem diagnosis. Neurology. 2005;65:1232-1238.
41. Cahn-Weiner DA, Grace J, Ott BR, et al. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsych Neuropsychol Behav Neurol. 2002;15:79-87.
42. Galvin JE. Dementia with Lewy bodies. Arch Neurol. 2003;60:1332-1335.
43. Fahn S, Elton RL, UPDRS Development committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., eds. Recent Developments in Parkinson's disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-163.
44. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19:448-450.
45. Goldman WP, Baty JD, Buckles VD, et al. Cognitive and motor functioning in Parkinson disease - subjects with and without questionable dementia. Arch Neurol. 1998;55:674-680.
46. Harrison JE, Stowe I, Owen AM. Parkinson's disease. In: Harrison JE, Owen AM, eds. Cognitive Deficits in Brain Disorders. London: Taylor & Francis; 2002:197-216.
47. Berardelli A, Rothwell JC, Thompson PD, et al. Pathophysiology of bradykinesia in Parkinson's disease. Brain. 2001;124:2131-2214.
48. Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991;114:2095-2122.
49. Jacobs DM, Marder K, Cote LJ, et al. Neuropsychological characteristics of preclinical dementia in Parkinsons-disease. Neurology. 1995;45:1691-1696.
50. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol. 2005;62:467-472.
51. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord. 2002;17:1221-1226.
52. Amieva H, Lafont S, Rouch-Leroyer I, et al. Evidencing inhibitory deficits in Alzheimer's disease through interference effects and shifting disabilities in the Stroop test. Arch Clin Neuropsych. 2004;1:792-803.
53. Lamar M, Swenson R, Kaplan E, et al. Characterizing alterations in executive functioning across distinct subtypes of cortical and subcortical dementia. Clinical Neuropsychologist. 2001;18:22-31.
54. Owen AM, Iddon JL, Hodges JR, et al. Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia. 1997;35:519-532.
55. Jordan N, Sagar HJ, Cooper JA. Cognitive components of reaction-time in Parkinsons disease. J Neurol Neurosurg Psychiatry. 1992;55:658-664.
56. Mahieux F, Fenelon G, Flahault A, et al. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64:178-183.
57. Homann CN, Suppan K, Wenzel K, et al. The bradykinesia akinesia incoordination test (BRAIN TEST (c)), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord. 2000;15:641-647.
58. Mayeux R, Stern Y, Sano M, et al. Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology. 1987;37:1130-1134.
59. Russ MO, Seger L. The effect of task complexity on reaction times in memory scanning and visual discrimination in Parkinsons disease. Neuropsychologia. 1995;33:561-575.
60. Reitan RM. Manual for Administration of Neuropsychological test batteries for adults and children. Indianapolis 1969.
61. Tiffin J. Purdue Pegboard: Examiner Manual. Chicago: Science Research Associates; 1968.
62. Botwinick J, Storandt M. Speed functions, vocabulary ability, and age. Percept Mot Skills. 1973;36:1123-1128.
63. Faust ME, Balota DA, Spieler DH, et al. Individual differences in information-processing rate and amount: implications for group differences in response latency. Psychol Bull. 1999;125:777-799.
64. Lauderbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am. 2004;27:801-825.
65. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
66. Aarsland D, Larsen JP, Kim NH, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:492-496.
67. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528-536.
68. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord. 2005;20(suppl 11):S23-S29.
69. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 2005;4:605-610.
70. Fenelon G, Goetz CG, Keranberg A. Hallucinations in Parkinson's disease in the prelevodopa era. Neurology. 2006;66:93-98.
71. Starkstein SE, Petracca G, Chemerinski E, et al. Depression in classic versus akinetic-rigid Parkinson disease. Mov Disord. 1998;39:1441-1445.
72. Stein MD, Heuser IJ, Juncos JL, et al. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990;147:217-220.
73. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology-Later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59:102-112.
74. Jellinger K. The association of incident dementia with mortality in PD. Neurology. 2003;61:424.
75. Bancher C, Braak H, Fischer P, et al. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimers and Parkinsons-disease patients. Neurosci Lett. 1993;162:179-182.
76. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology. 1997;49:1570-1576.
77. Yoshimura M. Pathological basis for dementia in elderly patients with idiopathic Parkinson's-disease. Eur Neurology. 1988;28:29-35.
78. Jellinger K. Neuropathological substrates of Alzheimers-disease and Parkinsons-disease. J Neural Transm. 1987;24:109-129.
79. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 2000;54:1916-1921.
80. Haroutunian V, Serby M, Purohit DP, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol. 2000;57:1145-1150.
81. Braak H, Braak E, Yilmazer D, et al. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J Neural Transm. 1996;48(suppl):1-6.
82. Ince PG, Matthews F, Bayne C. Pathological correlates of dementia. Lancet. 2002;359:625.
83. Jendroska K. The relationship of Alzheimer-type pathology to dementia in Parkinson's disease. J Neural Transm. 1997;(suppl):23-31.
84. Vermersch P, Delacourte A, Javoyagid F, et al. Dementia in Parkinsons-disease: biochemical evidence for cortical involvement using the immunodetection of abnormal tau-proteins. Ann Neurol. 1993;33:445-450.
85. Kosaka K. Diffuse Lewy body disease. Neuropathology. 2000;20:S73-S78.
86. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
87. Ball J. Current advances in Parkinson's disease. Trends Neurosci. 2001;24:367-369.
88. Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric-symptoms predict faster cognitive decline in Alzheimers-disease. Arch Neurol. 1994;51:676-681.
89. Emre M. Dementia associated with Parkinson's disease. Lancet Neurology. 2003;2:229-237.
90. Heilig CH, Knopman DS, Mastri AR, et al. Dementia without Alzheimer pathology. Neurology. 1985;35:762-765.
91. Rub U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging. 2002;23:245-254.
92. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol. 1988;45:497-501.
93. Zweig RM, Cardillo JE, Cohen M, et al. The locus ceruleus and dementia in Parkinson's disease. Neurology. 1993;43:986-991.
94. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983;275:321-328.
95. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alz Dis Assoc Disord. 1993;7:69-79.
96. Rinne JO. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res. 1989;317:325-332.
97. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 1996;274:1197-1199.
98. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106-108.
99. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164-173.
100. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.
101. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. 2005;20(suppl 12):S77-S82.
102. Williams-Gray CH, Foltynie T, Lewis SJ, et al. Cognitive deficits and psychosis in Parkinson's disease: a review of the pathophysiology and therapeutic options. CNS Drugs. 2006;20:477-505.
103. Leroi I, Collins D, Marsh L. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review. J Neurol Sci. 2006, June 26 Epub ahead of print.
104. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.
105. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Conchrane Database Syst Rev. 2006;1:CD004747.
106. Fuchs GA, Gemende I, Herting B, et al. Dementia in idiopathic Parkinson's syndrome. J Neurol. 2004;251(suppl 6):28-32.
107. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-2518.
108. Wesnes KA, McKeith I Edgar C, Ere M, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson's disease. Neurology. 2005;65:1654-1656.
109. Linazasoro G, Lasa A, Van Blercom N. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study. Clin Neuropharmacol. 2005;28:176-178.
110. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double-blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934-939.
111. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:937-941.
112. Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006;7:418-423.
113. Galvin JE. Alzheimer's disease: diagnosis and treatment across the spectrum. App Neurol. 2005;(suppl 1):1-16.
114. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633-637.
115. Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006;253:171-175.
116. Papapetropoulos S, Lieberman A, Gonzales J, et al. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease. Acta Neurol Scand. 2005;111:353-359.
117. Perry RH, Irving S, Blessed G, et al. Senile dementia of the Lewy body type. J Neurol Sci. 1990;95:119-139.